On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD). Hives (also called urticaria) refer to raised and splotchy areas of skin that can be caused by an allergic reaction. 14 of 15 study participants (93%) enrolled in both dose cohorts (n=15) achieved a clinical response within the 6-week preliminary ...

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating b ...

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Conference D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (650) 549-1 ...

Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to BEACON study Initial data from BEACON study through 240mg dosing cohort to be presented in 4Q24 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c- ...

"We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our Board," said Thomas Wiggans, Chairperson of Jasper's Board. "Svetlana has led several significant partnerships with large pharma and has particular expertise in the areas of strategic planning and business development. We look forward to capitalizing on her insights as the briquilimab development program continues to expand in mast cell diseases. I'd also like to thank Anna French for instrumental contri ...

"I am excited to join Jasper's Board at an important phase in the company's growth," said Dr. Lucas. "I believe that briquilimab has the potential to serve as an important and differentiated therapeutic in a large number of diseases, and I look forward to contributing to Jasper's continued progress in delivering more treatment options to patients in need." About Jasper Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harb ...

REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New ...

| --- | |----------------------------------| | | | Joyce Allaire (investors) | | LifeSci Advisors | | 617-435-6602 | | jallaire@lifesciadvisors.com | | Alex Gray (investors) | | Jasper Therapeutics 650-549-1454 | | agray@jaspertherapeutics.com | | Lauren Walker (media) | | Real Chemistry | | 646-564-2156 | Details of the presentation are below: About Briquilimab Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic ...

REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematology Associati ...